Meet the leadership team that's helping transform surgery, advance care, and change lives.
Meet the leadership team that's helping transform surgery, advance care, and change lives.
Chief Executive Officer
Chris Barry serves as our chief executive officer and a member of the NuVasive Board of Directors.
Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.
Matt Link serves as our president, and is responsible for NuVasive’s portfolio and commercial strategy. This includes oversight of our global commercial teams, product and systems development, NuVasive Clinical Services (NCS), NuVasive Specialized Orthopedics (NSO) and commercial enablement such as global marketing and clinical professional development.
Mr. Link’s previous roles at NuVasive include executive vice president, strategy, technology and corporate development; president, U.S. commercial; executive vice president of U.S. sales; and senior vice president of sales for the Company’s U.S. Eastern region. Prior to joining NuVasive, he held several regional sales positions with DePuy Orthopedics and DePuy Spine. Mr. Link holds bachelor’s degrees in physical education and sports medicine from the University of Virginia.
Executive Vice President and Chief Financial Officer
Matt Harbaugh serves as our executive vice president and chief financial officer (CFO), and is responsible for all financial aspects of the Company, including accounting, financial planning and analysis, tax and treasury.
Prior to this role, Mr. Harbaugh worked at Mallinckrodt plc for nearly 10 years, most recently serving as the president of the specialty generics business, and spent more than five years as Mallinckrodt’s CFO. Prior to this, he spent 10 years at Covidien in various finance leadership roles, and, most notably, helped lead the spin-off of Covidien Pharmaceuticals as Mallinckrodt Pharmaceuticals in July 2013. In addition, Mr. Harbaugh served in various finance leadership roles at Monsanto Company within its international regions. He received a bachelor’s degree in business administration from Saint Louis University and an executive master of business administration degree from Kellogg School of Management at Northwestern University.
Senior Vice President, Global Operations
Dale Wolf serves as senior vice president, global operations, and is responsible for supply chain & field logistics, distribution, manufacturing, quality assurance, international operations, real estate & facilities and a business transformation office. Mr. Wolf was most recently vice president of manufacturing for NuVasive, where he led our West Carrollton, Ohio, facility and the growth and development of manufacturing strategy.
Prior to joining NuVasive, Mr. Wolf spent nearly two decades at General Electric (GE), and has extensive experience in medical device manufacturing operations. He held various leadership roles managing GE Healthcare manufacturing facilities, streamlining new product introductions, and implementing Lean Six Sigma and continuous improvement platforms. Mr. Wolf holds a bachelor’s degree in mechanical engineering from the University of Wisconsin-Madison, and a Six Sigma Green Belt certification.
Senior Vice President, General Counsel and Corporate Secretary
Nathaniel Sisitsky, Esq., serves as our senior vice president, general counsel and corporate secretary, and is responsible for NuVasive’s legal functions, global risk and integrity and the NuVasive Spine Foundation.
Previously, Mr. Sisitsky served as NuVasive’s vice president and associate general counsel. Before joining NuVasive, he held a variety of legal positions, including vice president and associate general counsel, corporate governance and securities and M&A at CareFusion Corporation; and vice president, legal – corporate finance, at American Tower Corporation. Prior to joining American Tower, Mr. Sisitsky was a junior partner in the corporate department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale). Mr. Sisitsky holds bachelor’s degrees in political science and economics from Emory University, and a Juris Doctor degree from New York University School of Law.
Chief Human Resources Officer
Lucas Vitale serves as our chief human resources officer and is responsible for the Company’s human resources function, including sales training, talent management, compensation and organizational development.
Mr. Vitale’s prior roles at NuVasive include vice president, commercial talent development; vice president of human resources; and vice president of talent. Before joining NuVasive, he held multiple human resources leadership positions focused on driving culture and talent strategies at Life Technologies. Mr. Vitale holds bachelor’s degrees in marketing and finance from Hawaii Pacific University and a master’s degree in industrial/organizational psychology from Alliant International University.
Vice President, Information Technology
Aviva McPherron serves as our vice president, information technology, and is responsible for the Company’s information technology organization. Ms. McPherron’s previous roles include vice president of enterprise applications and senior director of business solutions.
Before joining NuVasive, she was director of operations for Tapestry Solutions, a Boeing Company, and has held multiple technical leadership positions delivering transformative solutions. Ms. McPherron holds a bachelor’s degree in mechanical engineering from Stanford University.
Vice President, Internal and External Affairs
Suzanne Hatcher serves as our vice president, internal and external affairs, and is responsible for the Company’s public relations, investor relations and internal communications functions.
Before joining NuVasive, she held a variety of corporate communications positions at such San Diego-based companies as Cubic Corporation, Life Technologies, CareFusion and Sempra Energy. Ms. Hatcher holds a bachelor’s degree in advertising and English from University of Miami.
Vice President, Clinical, Medical, and Regulatory Affairs
Kyle Malone serves as our vice president of clinical, medical, and regulatory affairs and is responsible for NuVasive’s global regulatory and clinical strategies. Over the past decade, Mr. Malone has held positions of increasing leadership within NuVasive’s clinical teams and has served in various cross-functional management capacities.
Before joining NuVasive, he served as the director of research for the NNI Research Foundation in Las Vegas, Nevada. Mr. Malone holds dual master’s degrees from Tulane University and The Johns Hopkins University in neuroscience and music / pedagogy, respectively.
Senior Vice President, Strategy and Corporate Development
Sean Freeman serves as our senior vice president, strategy and corporate development. In this capacity, he oversees global corporate and geographic strategy, leads inorganic and venture initiatives, and manages the integration function.
Prior to joining NuVasive, Mr. Freeman held the same role at the Cole-Parmer Instrument Company and led corporate development at Life Technologies, a global life sciences tools company acquired by ThermoFisher in 2015. Prior to Life Technologies, he was an investment banker in the M&A group at Merrill Lynch & Co. in New York. Mr. Freeman is a CFA charterholder, holds a bachelor’s degree in commerce from the University of the Witwatersrand, and earned a master’s degree in business administration from The Wharton School at the University of Pennsylvania.
Senior Vice President, Government and Regulations Strategy
James Garrett serves as our senior vice president, government and regulations strategy, and is responsible for designing and executing non-market (i.e., social, political and legal) strategies to assess opportunities and threats that may impact the Company’s business results, and for leading key global initiatives (e.g., compliance with the EU Medical Device Regulation).
Mr. Garrett’s prior role at NuVasive was leader of business and quality systems, responsible for global risk and integrity, regulatory affairs, quality affairs, information technology, and environmental health and safety. He has also served as NuVasive’s chief risk and compliance officer, and associate general counsel. Before joining the Company, he served as Counsel at DLA Piper where he focused on business, securities and corporate litigation. Mr. Garrett received his bachelor’s degree from the University of California, Los Angeles, and law degree from the University of San Diego School of Law.
Chris Barry serves as our chief executive officer and a member of the NuVasive board of directors.
Prior to joining NuVasive, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Mr. Barry provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, advanced surgical technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.
Vickie L. Capps has served as a member of our board of directors since June 2015. Ms. Capps is currently a senior advisory board member of Consonance Capital Partners, a healthcare investment firm. Ms. Capps previously served as chief financial officer of several public and private companies. From July 2002 to December 2013, Ms. Capps served as the executive vice president, chief financial officer and treasurer of DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP. She also serves on the board of directors of Amedisys, Inc. and Otonomy, Inc. Ms. Capps is a California certified public accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. She earned a bachelor’s degree in business administration/accounting from San Diego State University.
John DeFord, Ph.D. has served as a member of our board of directors since February 2018. Dr. DeFord is currently the executive vice president and chief technology officer for Becton, Dickinson and Company, a global medical technology company. Dr. DeFord previously served as the senior vice president, research and development, interventional segment for Becton Dickinson from December 2017 to June 2018 following its acquisition of C.R. Bard, Inc., where he had served as senior vice president, science, technology and clinical affairs since June 2007. Dr. DeFord joined Bard in 2004, and served in science and technology roles of increasing responsibility since that time. Prior to joining Bard, Dr. DeFord was managing director of Early Stage Partners LP, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was president and CEO of Cook Incorporated, a privately held medical device manufacturer. Dr. DeFord is a graduate of Purdue University with a bachelor’s degree and master’s degree in electrical engineering and a Ph.D. in electrical/biomedical engineering.
Robert F. Friel has served as a member of our board of directors since February 2016. Mr. Friel most recently served as the chairman and chief executive officer of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, until his retirement in December 2019. Mr. Friel served as PerkinElmer’s chief executive officer since February 2008 and chairman since April 2009. From August 2007 to January 2019, Mr. Friel also served as PerkinElmer’s president. Since joining PerkinElmer in February 1999 as chief financial officer, Mr. Friel also held the roles of chief operating officer and vice chairman and president of PerkinElmer’s life and analytical sciences unit. Prior to joining PerkinElmer, he held several senior management positions with AlliedSignal, Inc., now Honeywell International. Mr. Friel currently serves as a member of the board of directors of Xylem, Inc. and West Pharmaceutical Services, Inc. Mr. Friel received a bachelor’s degree in economics from Lafayette College and a master’s degree in taxation from Fairleigh Dickinson University.
R. Scott Huennekens has served as a member of our board of directors since October 2018. Mr. Huennekens most recently served as the president, chief executive officer and chairman of the board for Verb Surgical, an independent start-up company formed by Google and Johnson & Johnson to develop surgical platforms including advanced surgical robotics, from August 2015 to December 2018. Prior to joining Verb Surgical, Mr. Huennekens was president, chief executive officer and a member of the board of directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens was president and chief executive officer at Digirad Corporation from 1997 to 2002, and held various management roles at Baxter Healthcare from 1993 to 1997. Mr. Huennekens currently serves as a member of the board of directors of ViewRay Inc. and Envista Holdings Corporation. Mr. Huennekens received a bachelor’s degree in business administration from the University of Southern California, and a master of business administration degree from Harvard Graduate School of Business.
Gregory T. Lucier has served as a member of our board of directors since December 2013 and as chairman of the board since May 2015. Mr. Lucier currently serves as the chief executive officer of Corza Health, Inc., a company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business. Mr. Lucier previously served as chief executive officer of NuVasive from May 2015 to November 2018. Mr. Lucier has over 25 years of executive management experience and served as chairman and chief executive officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until its acquisition by Thermo Fisher Scientific Inc. in February 2014 for $15.6 billion. Prior to joining Life Technologies, Mr. Lucier served as chief executive officer and president at GE Medical Systems Information Technologies, vice president for Global Services at GE Medical Systems and served as a corporate officer of the General Electric Corporation. In addition to serving as chairman of the board of NuVasive, he serves as a member of the board of directors of Catalent, Inc. and Dentsply Sirona Inc. Mr. Lucier received a bachelor’s degree with high distinction in industrial engineering from Pennsylvania State University and a master of business administration from Harvard Graduate School of Business.
Leslie V. Norwalk, Esq. has served as a member of our board of directors since May 2014. Ms. Norwalk is currently strategic counsel to Epstein Becker & Green, P.C., EBG Advisors and National Health Advisors. She also serves as a healthcare, regulatory and policy advisor to several private equity firms. Ms. Norwalk previously served the Bush Administration as the acting administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of Health Care Facilities and other federal health care initiatives. For four years prior to that, she was the agency’s deputy administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush Administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk serves as a director of Arvinas Inc., Magellan Health Inc., Neurocrine Biosciences, Inc., and Providence Service Corp., as well as several privately-held healthcare companies. She is also a member of APCO Worldwide’s International Advisory Council. Ms. Norwalk earned a JD degree from the George Mason University School of Law and a bachelor’s degree, cum laude, in economics and international relations from Wellesley College.
Donald J. Rosenberg has served as a member of our board of directors since February 2016. Since October 2007, Mr. Rosenberg has served as executive vice president, general counsel and corporate secretary of Qualcomm Incorporated, a global leader in the development and commercialization of wireless technologies. Prior to joining Qualcomm, he served as senior vice president, general counsel and corporate secretary of Apple Inc. Prior to that, Mr. Rosenberg held numerous positions at IBM Corporation, including senior vice president and general counsel. Mr. Rosenberg is a member of the International Advisory Board, University of California San Diego (UCSD) School of Global Policy and Strategy. He is also a member of the China Leadership Board for the 21st Century China Center at UCSD. He has served as an adjunct professor of law at New York’s Pace University School of Law, where he taught courses in intellectual property and antitrust law. He received a bachelor’s degree in mathematics from the State University of New York at Stony Brook and his JD degree from St. John’s University School of Law.
Daniel J. Wolterman has served as a member of our board since July 2015. Mr. Wolterman is currently chief executive officer of Wolterman Consulting LLC, a provider of strategic and operational consulting services to healthcare providers and other entities. From January 2018 to May 2019, Mr. Wolterman served as chief executive officer of ColubrisMX, Inc. and X-Cath, Inc., both privately held medical device companies. Mr. Wolterman previously served as president and chief executive officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. He has more than 38 years of experience in the healthcare industry and a long history of community involvement. Mr. Wolterman earned a bachelor’s degree in business administration, a master of business administration degree in finance from the University of Cincinnati and a master’s degree in healthcare administration from Xavier University.